AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03760497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restorative treatment
Description: For all groups, first the patients will be submitted to the anesthetic technique indicated with Lidocaine + Epinephrine 1: 100,000 (New DFL, Rio de Janeiro, Brazil), followed by absolute isolation with rubber sheet and metal clamp; then prophylaxis of the selected tooth will be performed with Robson's brush and pumice stone and water, surface washing and drying with cotton balls, removal of carious tissue or affected enamel without dentin support with sharp curettes or low-speed spherical drills. Subsequently, each group will follow the treatment protocols suggested by the manufacturer of restorative materials.
Study NCT05611294 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Topography Guided LASIK Surgery
Description: LASIK surgery, using corneal topography data in treatment profile, to correct myopia or myopia with astigmatism refractive error.
Study NCT05611294 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Small Incision Lenticule Extraction Surgery
Description: Corneal lenticule formation using a femtosecond laser, with subsequent lenticule extraction, to correct myopia or myopia with astigmatism refractive error.
Study NCT05365165 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Description: Sevoflurane will be applied during aortic cross- clamping in cardiac surgery
Study NCT04901039 — intervention group
Intervention type: OTHER
Intervention: Lung ultrasound
Description: Decompensated HF patients will be evaluated at admission and prior to hospital discharge with a range of tools including lung ultrasound imaging
Study NCT04901039 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: Comprehensive echocardiography with evaluation of filling pressures
Study NCT04901039 — intervention group
Intervention type: OTHER
Intervention: Peripheral venous pressure
Description: Assessment of peripheral venous pressure
Study NCT05330715 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Management
Description: Comparison if different strategies to manage acute emergencies in the pre-hospital setting.
Study NCT05563870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoluminal radiofrequency ablation
Description: Endoluminal Radiofrequency ablation (RFA) of the entire stricture length will be performed using the Habib probe. A current of 7W will be delivered for 90s intervals at a time. If multiple ablation sessions are needed in order to ablate the entire stricture lenght, there will be an overlap of ablated areas in order to ensure proper stricture treatment. Dilation of the stricture prior to RFA delivery will be performed if required. After RFA treatment, biliary drainage of all hepatic territories will be ensured.
Study NCT05563870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic biliary stenting
Description: Endoscopic biliary stenting will be performed via ERCP using multiple plastic stents, in order to ensure propper drainage of all accessed hepatic territories.
Study NCT05563870 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic biliary stenting
Description: Endoscopic biliary stenting will be performed via ERCP using multiple plastic stents, in order to ensure propper drainage of all accessed hepatic territories.
Study NCT06476639 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High-resolution bilateral groin ultrasound monitoring
Description: Participants in the Interventional Group will undergo surgical excision of the primary tumor, either via radical wide local excision or radical vulvectomy. Post-vulvar surgery, participants will receive a groin node ultrasound every 2 months and a clinical examination every 3 months, for a follow up period of 12 months. Senior imaging specialists review bilateral ultrasound scans for positive lymph nodes or suspicious findings, promptly sending reports to the primary care physician and trial manager if detected within 3 business days. Subsequently, participants consult their primary care physician for options. Depending on clinical judgment, they may be referred for LND or continue with bi-monthly ultrasounds based on preference and clinician guidance.
Study NCT04901039 — intervention group
Intervention type: OTHER
Intervention: Magnetic resonance imaging
Description: Cardiac magnetic resonance imaging
Study NCT04901039 — intervention group
Intervention type: OTHER
Intervention: Pulmonary scintigraphy
Description: Assessment of pulmonary perfusion with scintigraphy
Study NCT06548802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib was given 4mg once daily, with the first dose taken within 24 hours of the appearance of lung injury and continued for 14 days.
Study NCT06046703 — intervention group
Intervention type: OTHER
Intervention: Daily nutritional intake
Description: Nutritional intake with a focus on vitamin B12, but also other micronutrients and macronutrients
Study NCT04679831 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ujiplus®
Description: Ujiplus® flour, a nutritional supplement will be used to prepare porridge, and each child will be given a serving of 300 ml every school day for 90 days.
Study NCT04679831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel 400mg
Description: 400mg of Praziquantel will be given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300 ml per every school day for 90 days,
Study NCT06269250 — intervention group
Intervention type: OTHER
Intervention: Policy Change
Description: There will be a change with the digitalization in the health care system with the beginning of the year 2024 and between Wave 1 and Wave 2
Study NCT05237895 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum Endocan Levels
Description: Detection of Serum Endocan Levels and detection of possible diagnostic association with gestational diabetes
Study NCT05525026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-785-7
Description: Treatment with the BTL-785-7 applicator to the BTL-785F system.
Study NCT04830267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab
Description: Camrelizumab 200mg IV starting day 1 and then every 2 weeks thereafter. Treatment with Camrelizumab will continue until progression or unacceptable toxicity.
Study NCT04830267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg IV starting day 1 and then every 2 weeks thereafter. Treatment with Camrelizumab will continue until progression or unacceptable toxicity.
Study NCT04830267 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Image guided, stereotactic body radiotherapy (27 Gy over 3 fractions given every other day) to a single lesion to start by study day 14 (study day 1 is day of first dose of Camrelizumab).
Study NCT05137561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PSMA PET guided prostate biopsy
Description: PSMA PET-guided prostate biopsy from PSMA avid prostatic lesion will be done.
Study NCT05137561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI directed TRUS guided prostate biopsy
Description: TRUS guided MR directed Cognitive fusion prostate biopsy based on the PIRADS scoring
Study NCT05604599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal dexmedetomidine
Description: 45 -60 min before the operation, patients will receive dose of dexmedetomidine 1microgram/kg diluted in 10ml 0.9% saline administered to each naris as drops + infusion saline
Study NCT05604599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous dexmedetomidine
Description: patients will receive loading dose of dexmedetomidine 1 µg/kg diluted in 10ml 0.9% saline infused over 45- 60 min before induction of anesthesia, followed by continuous infusion of (0.4 µ g/kg/h) + intranasal saline.
Study NCT06253039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated sprint
Description: * The group will endure four weeks (8 sessions) of the assigned training program in addition to the regular swimming training.~* Data collection sessions: All groups will be evaluated before and after the supervised training period in three testing sessions in normoxia separated by at least 24 hours within 7 days.~* Training sessions: will be performed in the ski ergometer and consist of 4 sets of 5x6s all-out sprints with 24s and 5 min of passive rest between the sprints and sets, respectively.
Study NCT06253039 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Repeated sprint
Description: * The group will endure four weeks (8 sessions) of the assigned training program in addition to the regular swimming training.~* Data collection sessions: All groups will be evaluated before and after the supervised training period in three testing sessions in normoxia separated by at least 24 hours within 7 days.~* Training sessions: will be performed in the ski ergometer and consist of 4 sets of 5x6s all-out sprints with 24s and 5 min of passive rest between the sprints and sets, respectively.
Study NCT06357650 — intervention group
Intervention type: OTHER
Intervention: No intervention. This is an observational study
Description: This is an observational study. Hence there is no intervention
Study NCT06050538 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transabdominal preperitoneal (TAPP) using polyprolene mesh
Description: Transabdominal preperitoneal (TAPP) approach for recurrent inguinal hernia using polyprolene mesh
Study NCT06050538 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total extraperitoneal (TEP) hernioplasty using polyprolene mesh
Description: Total extraperitoneal (TEP) approach for recurrent inguinal hernia using polyprolene mesh
Study NCT06128265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: Extending time in bed by 2 hours (going to bed earlier and/or waking up later)
Study NCT06128265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Regularity
Description: Consistent bedtimes (within 30min)
Study NCT05544890 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.~Other Names:~- Therapeutic exercise
Study NCT05544890 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.~Other Names:~- Manipulation
Study NCT05544890 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotape
Description: All patients will start learning how to activate the transversus abdominal muscle in the first training session. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rest between series will be of 30 seconds, and between exercise of 2-3 minutes.~Other Names:~- Kinesiotaping
Study NCT05197231 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resisted knee extension exercise
Description: Patients in the intervention group will perform a seated knee extension exercise in three sets. Resistance will be adjusted using ankle weights, targeting 8-12 repetitions per set.
Study NCT05197231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV amino acids
Description: IV amino acids (Glavamin, Fresenius Kabi) delivered by continuous infusion at a rate of 0.1 g/kg/h. The infusion is started immediately prior to physiotherapy and continued until all blood samples required for outcome assessment are collected during a 90-minute resting period after the exercise session.
Study NCT05197231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV amino acids
Description: IV amino acids (Glavamin, Fresenius Kabi) delivered by continuous infusion at a rate of 0.1 g/kg/h. The infusion is started immediately prior to physiotherapy and continued until all blood samples required for outcome assessment are collected during a 90-minute resting period after the exercise session.
Study NCT06399874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nightmare Deconstruction and Reprocessing
Description: A psychotherapy that uses exposure to nightmare images for trauma activation in order to facilitate trauma memory reconsolidation
Study NCT06399874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NightWare
Description: Wristband device that detects physiologic signals during sleep that indicate a possible nightmare and gently vibrates to rouse the sleeper without fully waking them.
Study NCT06549829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional optimization-led triple prehabilitation Intervention
Description: The nutritional status of the patients was assessed together with the clinical nutritionist to develop an individualized nutritional plan. The experimental group used ordinary dietary supplementation + transoral nutritional supplementation, and the control group used ordinary dietary supplementation. The target energy was basal energy metabolism level \* physical activity level, physical activity level was male: 1.55 female: 1.56; basal energy level was basal metabolism standardized value \* body weight (basal metabolism standardized value for obese patients was 25; basal metabolism standardized value for normal or emaciated patients was 30). Add 600kcal capacity supplement to this. Exercise workouts focused on increasing lung capacity and cardiorespiratory tolerance. Specialized psychological interventions.
Study NCT06549829 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional triple prehabilitation Intervention
Description: Conventional triple prehabilitation: ordinary dietary supplementation; exercise workouts focused on increasing lung capacity and cardiorespiratory tolerance; specialized psychological interventions.
Study NCT06473909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD25 antibody combined glucocorticoid as first-line treatment
Description: CD25 antibody combined glucocorticoid as first-line treatment
Study NCT04970004 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No study intervention will be administered as part of this study.
Study NCT04928261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Patients with early-stage HER2-positive breast cancer who demonstrate a pathological complete response at time of surgery will be treated with HER2 targeted therapy for a total of 9 treatments every 3 weeks (or its equivalent if given weekly) including the treatment received preoperatively.
Study NCT05141305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenecteplase (0.25 mg/kg, Max 25 mg)
Description: tenecteplase (0.25 mg/kg) is being used.
Study NCT05141305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard medical treatment
Description: Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone are being used.
Study NCT06548867 — intervention group
Intervention type: DRUG
Intervention: Cabozantinib
Description: Patients must have been treated with cabozantinib after one or more previous therapies for mRCC, as per clinical practise.
Study NCT05400148 — intervention group
Intervention type: DRUG
Intervention: Bupivacaine Hydrochloride
Description: Patients who were administered an analgesic PENG block with a dose of 2.5mg/kg with either lov (\<20ml) or high volume (>20ml)
Study NCT05870904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry Needling includes the insertion of a fine, strong filiform needle without presentation of any pain relieving medicine.~Ischemic pressure is usually applied to trigger point, in what is known as trigger point therapy, where enough continuous pressure is applied to a trigger point within a tolerable measure of pain, and as discomfort is decreased, extra pressure is gradually applied
Study NCT05870904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: Dry Needling includes the insertion of a fine, strong filiform needle without presentation of any pain relieving medicine.~Ischemic pressure is usually applied to trigger point, in what is known as trigger point therapy, where enough continuous pressure is applied to a trigger point within a tolerable measure of pain, and as discomfort is decreased, extra pressure is gradually applied
Study NCT04944108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LISA approach
Description: Participants will be randomized to administer surfactant in a preterm manikin by using the LISA approach (thin catheter) or the INSURE approach (tracheal tube)
Study NCT04944108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insure approach
Description: Participants will be randomized to administer surfactant in a preterm manikin by using the INSURE approach (tracheal tube)
Study NCT06075225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is asministrated with the dose of 5mg bid for 28 days. If no signs of aGvHD, the dose of ruxolitinib is gradually tapered within the following 16 days.
Study NCT06014944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
Description: neoadjuvant therapy for short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody for PMMR / MSS type middle and low locally advanced rectal cancer.
Study NCT05273684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Participants will undergo 4x4 and 1x10 minutes of interval training on two separate days.
Study NCT04870437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal phototherapy
Description: The principle of ECP is to collect mononucleated cells from the blood by centrifugation. After purification, the mononucleated cells are incubated ex-vivo with a photo-activatable DNA intercalating agent (8-methoxypsoralen, UVADEX®), then re-injected to the patient.
Study NCT06355570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal Pictures
Description: Digital photos will be shown continuously at the patient's bedside for 12 hours a day (between 8 am to 8 pm).
Study NCT06355570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Videos
Description: Family-recorded videos will be played three times at specific hours of the day - 9 am, 2 pm and 7 pm - throughout patient stay in the ICU
Study NCT06355570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Videos - Intervention as required
Description: The last video shown will be re-played upon patient request and/or if patients develop ICU delirium.
Study NCT04550130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TLA Gut™
Description: The medical device to be investigated is named Tailored Leukapheresis (TLA) Gut™. The device comprises a column that has been designed for extracorporeal leukapheresis to specifically remove chemokine (C-C motif) receptor 9 (CCR9) expressing immunological cell populations including human leukocyte antigen DR isotype (HLA-DRhi ) monocytes from the circulation. This is achieved by integrating a strong affinity binding between the gut homing cell receptor, CCR9, and its cognate ligand, thymus-expressed chemokine (TECK) or chemokine ligand 25 (CCL25). Those blood cells that express CCR9 will bind to presented Biotinylated thymus-engineered chemokine (bTECK) on the matrix by a strong receptor ligand interaction, remaining bound to the matrix. Blood cells that do not express the receptor pass through the column unchanged and are returned to the patient.
Study NCT06427460 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Central-boost ablative dose delivered by stereotactic body radiation therapy
Description: An inner and complete gross tumor volume (iGTV) is created within the gross tumor volume (GTV). For the liver or lung tumor, the convetional radiation dose is 35-45Gy/5f. Regarding the pancreatic tumor or retroperitoneal tumor, the radiation dose is 30-40Gy/5f. Hence, the radiation dose of iGTV should not be less than 120% of the dose of GTV.
Study NCT05542238 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One bout of moderate-intensity sub-maximal aerobic exercise
Description: The intervention is a 20-min acute exercise using arm ergometer
Study NCT05542238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One bout of moderate-intensity sub-maximal aerobic exercise
Description: The intervention is a 20-min acute exercise using arm ergometer
Study NCT06342869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anesthesia
Description: application of different anesthesia techniques
Study NCT06237517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of Vasomotion of People With Idiopathic Chilblains
Description: Investigation of vasomotion of people with and without idiopathic chilblains
Study NCT06237517 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of Vasomotion of People With Idiopathic Chilblains
Description: Investigation of vasomotion of people with and without idiopathic chilblains
Study NCT05216081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)
Description: Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.